Peptide‐based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases
Top Cited Papers
- 25 February 2004
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 24 (3) , 357-397
- https://doi.org/10.1002/med.20002
Abstract
An Erratum has been published for this article in Medicinal Research Reviews 2004;24:685–686. Small synthetic receptor‐binding peptides are the agents of choice for diagnostic imaging and radiotherapy of cancers due to their favorable pharmacokinetics. Molecular modification techniques permit the synthesis of a variety of bioactive peptides with chelating groups, without compromising biological properties. Various techniques have been developed that allow efficient and site‐specific labeling of peptides with clinically useful radionuclides such as 99mTc, 123I, 111In, and 18F. Among them, 99mTc is the radionuclide of choice because of its excellent chemical and imaging characteristics. Recently, many 99mTc‐labeled peptides have proven to be useful imaging agents. Beside 99mTc‐labeled peptides, several peptides radiolabeled with 111In and 123I have been prepared and characterized. In addition, 18F‐labeled peptides hold clinical potential due to their ability to quantitatively detect and characterize a variety of human diseases using positron‐emission tomography. The availability of this wide range of peptides labeled with different radionuclides offers multiple diagnostic and therapeutic applications. Various receptors are over‐expressed in particular tumor types and peptides binding to these receptors can be used to visualize tumor lesions scintigraphically. Thus, radiolabeled peptides have potential use as carriers for the delivery of radionuclides to tumors, infarcts, and infected tissues for diagnostic imaging and radiotherapy. Many radiolabeled peptides are currently under investigation to determine their potential as imaging agents. These peptides are designed mainly for thrombus, tumor, and infection/inflammation imaging. This article presents recent developments in small synthetic peptides for imaging of thrombosis, tumors, and infection/inflammation. © 2004 Wiley Periodicals, Inc. Med Res Rev, 24, No. 3, 357–397, 2004Keywords
This publication has 110 references indexed in Scilit:
- Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo αvβ3 integrin related tumor imagingNuclear Medicine and Biology, 2003
- Biodistribution and catabolism of 18F-labeled neurotensin(8–13) analogsPublished by Elsevier ,2002
- Non‐invasive determination of the αvβ3 integrin expression using [18F]galacto‐RGD and petJournal of Labelled Compounds and Radiopharmaceuticals, 2001
- [18F]‐ET‐1 a pet radioligand for the endothelin receptor system — radiochemistry, position of label and in vivo biodistributionJournal of Labelled Compounds and Radiopharmaceuticals, 2001
- Evaluation of a 64Cu‐labeled bombesin analogue for diagnosis of gastrin‐releasing peptide receptor positive tumors by micropet imagingJournal of Labelled Compounds and Radiopharmaceuticals, 2001
- Fibrin avid 99mTC‐peptide for imaging thrombosisJournal of Labelled Compounds and Radiopharmaceuticals, 2001
- 188Re- and 99mTc-MAG3 as prosthetic groups for labeling amines and peptides: Approaches with pre- and postconjugate labelingNuclear Medicine and Biology, 1998
- Fluorine-18-labeled [Nle4,d-Phe7]-α-MSH, an α-melanocyte stimulating hormone analogueNuclear Medicine and Biology, 1997
- Visualization of the thymus by substance P receptor scintigraphy in manEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- 123I-vasoactive intestinal peptide (VIP) receptor scanning: Update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tractNuclear Medicine and Biology, 1996